Comparison

Biological comparison

This compares mechanisms and evidence profiles. It is not a ranking, a recommendation, or a safety assessment.

Mandelic acid only

  • Formation of the cornified envelope

Shared pathways

  • No shared curated pathways

L-Ascorbic acid only

  • Collagen biosynthesis and modifying enzymes
  • Detoxification of reactive oxygen species
  • Melanin biosynthesis

Mandelic acid

C8H8O3 · Exfoliant

Single human studyOne curated human study — the finding has not been independently repeated in this dataset.

Mandelic acid is an aromatic alpha hydroxy acid. Its larger molecular size relative to glycolic acid is the usual explanation offered for slower penetration, though comparative human data are limited.

Targets

  • Corneodesmosin (CDSN)modulates (medium confidence)
  • Kallikrein-7 (KLK7)modulates (low confidence)
  • Tyrosinase (TYR)inhibits (low confidence)

L-Ascorbic acid

C6H8O6 · Antioxidant

Repeated (2 studies)Two independent human studies point the same way; more replication would strengthen this.

L-ascorbic acid is vitamin C: a water-soluble reducing agent and an essential cofactor for the prolyl and lysyl hydroxylases that mature collagen.

Targets

  • Prolyl 4-hydroxylase subunit alpha-1 (P4HA1)activates (high confidence)
  • Procollagen-lysine 5-dioxygenase (PLOD1)activates (high confidence)
  • Tyrosinase (TYR)inhibits (low confidence)
  • Sodium-dependent vitamin C transporter 2 (SLC23A2)targets (medium confidence)

Evidence engine

Moderate

Some human evidence exists, but replication or sample sizes are limited.

Skinceptor Evidence Index

46

experimental · of 100

This index is a research-navigation aid describing how much evidence exists and how it was produced. It is not a medical safety score, an efficacy guarantee, or a clinical recommendation.

Study composition

  • Human1
Total studies
1
Human studies
1
Largest sample
40
Range
2018–2018

Index breakdown

  • Study design quality70% × 28%

    Mean design weight across curated studies (meta-analysis 1.0, RCT 0.9, other human 0.7, review 0.45, animal 0.35, in-vitro 0.25).

  • Human evidence share33% × 22%

    Proportion of curated evidence measured in people rather than cells or animals.

  • Evidence volume32% × 14%

    Log-scaled count of curated studies, so volume alone cannot dominate the score.

  • Largest sample size53% × 12%

    Log-scaled largest reported sample size across curated human studies.

  • Replication33% × 12%

    Independent human studies, capped at three; one study is never treated as replicated.

  • Recency60% × 7%

    Linear decay over a twenty-year window from the most recent curated publication.

  • Source traceability0% × 5%

    Share of curated studies with a verified PMID or DOI in this dataset.

How is this determined? →

Insufficient comparable evidence for quantitative synthesis.

Evidence engine

Moderate

Some human evidence exists, but replication or sample sizes are limited.

Skinceptor Evidence Index

58

experimental · of 100

This index is a research-navigation aid describing how much evidence exists and how it was produced. It is not a medical safety score, an efficacy guarantee, or a clinical recommendation.

Study composition

  • Human1
  • Randomised controlled trial1
  • In-vitro3
  • Review2
Total studies
7
Human studies
2
Largest sample
19
Range
1991–2020

Index breakdown

  • Study design quality46% × 28%

    Mean design weight across curated studies (meta-analysis 1.0, RCT 0.9, other human 0.7, review 0.45, animal 0.35, in-vitro 0.25).

  • Human evidence share57% × 22%

    Proportion of curated evidence measured in people rather than cells or animals.

  • Evidence volume95% × 14%

    Log-scaled count of curated studies, so volume alone cannot dominate the score.

  • Largest sample size43% × 12%

    Log-scaled largest reported sample size across curated human studies.

  • Replication67% × 12%

    Independent human studies, capped at three; one study is never treated as replicated.

  • Recency70% × 7%

    Linear decay over a twenty-year window from the most recent curated publication.

  • Source traceability14% × 5%

    Share of curated studies with a verified PMID or DOI in this dataset.

How is this determined? →

Insufficient comparable evidence for quantitative synthesis.